Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Class A Common Stock, $0.00001 par value per share
-
Shares outstanding
-
4,564,846
-
Total 13F shares
-
260,820,186
-
Share change
-
+5,744,229
-
Total reported value
-
$1,719,746,530
-
Put/Call ratio
-
172%
-
Price per share
-
$6.59
-
Number of holders
-
263
-
Value change
-
+$28,653,319
-
Number of buys
-
148
-
Number of sells
-
97
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) as of Q3 2024
As of 30 Sep 2024,
RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) was held by
263 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
260,820,186 shares.
The largest 10 holders included
ARK Investment Management LLC, BAILLIE GIFFORD & CO, VANGUARD GROUP INC, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., Mubadala Investment Co PJSC, STATE STREET CORP, Kinnevik AB (publ), Sumitomo Mitsui Trust Group, Inc., and Nikko Asset Management Americas, Inc..
This page lists
262
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.